摘要 |
CCR5 antagonists having the following core structure Formula (I) (AA) are claimed, for the treatment of HIV, solid organ transplant rejection, graft v . host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis .</SDO AB>
|